We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
First Patient Enrolled in BrainStorm's Phase II ALS Trial
News

First Patient Enrolled in BrainStorm's Phase II ALS Trial

First Patient Enrolled in BrainStorm's Phase II ALS Trial
News

First Patient Enrolled in BrainStorm's Phase II ALS Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "First Patient Enrolled in BrainStorm's Phase II ALS Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BrainStorm Cell Therapeutics has announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.

BrainStorm’s Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or NurOwn™) in 48 ALS patients.

The trial is also being conducted at the University of Massachusetts Memorial (UMass) Hospital in Worcester, MA and the Mayo Clinic in Rochester, Minnesota.

Advertisement